<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Acute colonic pseudo-obstruction (Ogilvie's syndrome)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Acute colonic pseudo-obstruction (Ogilvie's syndrome)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Acute colonic pseudo-obstruction (Ogilvie's syndrome)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Camilleri, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nicholas J Talley, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shilpa Grover, MD, MPH, AGAF
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 31, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute colonic pseudo-obstruction (Ogilvie's syndrome) is a disorder characterized by acute dilatation of the colon in the absence of an anatomic lesion that obstructs the flow of intestinal contents. Pseudo-obstruction is characterized by signs and symptoms of a mechanical obstruction of the small or large bowel in the absence of a mechanical cause. Pseudo-obstruction may be acute or chronic and is characterized by the presence of dilation of the bowel on imaging. Other causes of colonic distension, including toxic megacolon, mechanical obstruction, and chronic intestinal pseudo-obstruction, are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/90291.html" rel="external">
          "Large bowel obstruction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1381.html" rel="external">
          "Toxic megacolon"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2639.html" rel="external">
          "Chronic intestinal pseudo-obstruction: Etiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H545980898">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute colonic pseudo-obstruction usually involves the cecum and right hemicolon, although occasionally colonic dilation extends to the rectum. Acute colonic pseudo-obstruction appears to be more common in men and in patients over the age of 60 years [
         <a href="#rid1">
          1
         </a>
         ]. However, cases have been reported in children [
         <a href="#rid2">
          2
         </a>
         ]. Acute colonic pseudo-obstruction is a rare complication of surgery, occurring in 0.06 percent of patients after cardiac surgery and 0.7 to 1.3 percent of patients with burns and after orthopedic surgery [
         <a href="#rid3">
          3,4
         </a>
         ]. In surgical patients, symptoms usually present at an average of five days postoperatively. From a national hospital admissions database, the estimated incidence of acute colonic pseudo-obstruction is approximately 100 cases out of 100,000 inpatient admissions per year [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2040770689">
         <span class="h1">
          ETIOLOGY AND PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute colonic pseudo-obstruction usually occurs in hospitalized or institutionalized patients in association with a severe illness or after surgery and in conjunction with a metabolic imbalance or administration of culprit medication  (
         <a class="graphic graphic_table graphicRef66068" href="/z/d/graphic/66068.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,3,6-8
         </a>
         ]. In a large, retrospective series that included 400 patients with acute colonic pseudo-obstruction, the most common predisposing conditions were nonoperative trauma, infection, and cardiac disease, each of which were associated with 10 percent of cases [
         <a href="#rid1">
          1
         </a>
         ]. In this series, cesarean section and hip surgery were the most common surgical procedures associated with acute colonic pseudo-obstruction. In a systematic review of 125 postpartum cases of acute colonic pseudo-obstruction, 62 (92 percent) occurred following cesarean section for varying indications including preeclampsia, multiple pregnancy, and antepartum hemorrhage/placenta previa [
         <a href="#rid9">
          9
         </a>
         ]. No specific risk factors could be identified for postpartum acute colonic pseudo-obstruction. Acute colonic pseudo-obstruction is also well-documented after kidney transplantation, and possible contributing factors include obesity, cumulative dose of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         received, and
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil [
         <a href="#rid10">
          10
         </a>
         ]. Rare cases have been reported in association with atrophic visceral myopathy with an extremely thin colonic wall, atrophic circular and longitudinal muscularis propria without inflammation or fibrosis, and unaffected ganglion cells and myenteric plexus [
         <a href="#rid11">
          11
         </a>
         ]. The cause of the smooth muscle atrophy was unclear, and the only potential association was with prior hypothyroidism [
         <a href="#rid11">
          11,12
         </a>
         ]. Other rare associations of acute colonic pseudo-obstruction are herpes zoster infection and pheochromocytoma [
         <a href="#rid13">
          13,14
         </a>
         ].
        </p>
        <p>
         The precise mechanism by which colonic dilation occurs in patients with acute colonic pseudo-obstruction is unknown. The association with trauma, spinal anesthesia, and pharmacologic agents suggests an impairment of the autonomic nervous system. Interruption of the parasympathetic fibers from S2 to S4 leaves an atonic distal colon and a functional proximal obstruction [
         <a href="#rid1">
          1,15
         </a>
         ]. However, there is no proposed mechanism to explain colonic dilation in those patients without obvious involvement of the parasympathetic nerves.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3328539433">
         <span class="h2">
          Clinical presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main clinical feature in patients with acute colonic pseudo-obstruction is abdominal distension. Abdominal distension usually occurs gradually over three to seven days but may develop rapidly within 24 to 48 hours. Approximately 80 percent of patients have associated abdominal pain. Nausea and vomiting may be seen in up to 60 percent of patients. Constipation and, paradoxically, diarrhea have also been reported in approximately 50 and 40 percent of patients, respectively [
         <a href="#rid1">
          1,16
         </a>
         ]. In rare cases, abdominal distention can cause dyspnea [
         <a href="#rid1">
          1,16
         </a>
         ]. It is recognized that a variant of recurrent acute or chronic colonic pseudo-obstruction with megacolon may be associated with a secretory diarrhea that results in fecal potassium loss and severe hypokalemia and is less likely to respond to usual treatments such as decompression or
         <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">
          neostigmine
         </a>
         [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
         On physical examination, the abdomen is tympanitic to percussion, but bowel sounds are present in almost 90 percent of patients [
         <a href="#rid1">
          1
         </a>
         ]. Approximately 65 percent of patients with a viable colon have mild abdominal tenderness on physical examination. However, the presence of fever, marked abdominal tenderness, and the presence of peritoneal signs (eg, guarding, rigidity, rebound tenderness) are suggestive of colonic ischemia or perforation or their impending development. (See
         <a class="medical medical_review" href="/z/d/html/2564.html" rel="external">
          "Colonic ischemia", section on 'Acute colonic ischemia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15075.html" rel="external">
          "Overview of gastrointestinal tract perforation", section on 'Presentations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3133043365">
         <span class="h2">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with acute colonic pseudo-obstruction, increasing colonic diameter accelerates the rise in tension on the colonic wall, increasing the risk of colonic ischemia and perforation. The risk of colonic perforation increases when cecal diameter exceeds 10 to 12 cm and when the distention has been present for greater than six days [
         <a href="#rid19">
          19
         </a>
         ]. The duration of dilation is probably more important than the absolute diameter of the colon [
         <a href="#rid20">
          20,21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4189929094">
         <span class="h1">
          DIAGNOSTIC APPROACH
         </span>
        </p>
        <p class="headingAnchor" id="H545980823">
         <span class="h2">
          Evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of acute intestinal pseudo-obstruction should be suspected in patients with abdominal distension or pain and a physical examination that reveals a distended and tympanitic abdomen. The goal of the evaluation is to establish the diagnosis of acute intestinal pseudo-obstruction, to assess for complications (ischemia, perforation, peritonitis), and to rule out other causes of colonic distension.
        </p>
        <p class="headingAnchor" id="H545980817">
         <span class="h3">
          Laboratory tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         We perform a complete blood count, electrolytes, and serum lactate levels. Given the rare cases associated with hypothyroidism and the fact it is eminently treatable, we also screen for hypothyroidism with a serum thyroid-stimulating hormone. In patients with a suspected perforation and diffuse peritonitis, serum aminotransferases, alkaline phosphatase, bilirubin, amylase, and lipase levels should be obtained to rule out other causes of acute abdominal pain. In patients with diarrhea, we also perform stool cultures and stool evaluation for
         <em>
          Clostridioides difficile
         </em>
         toxin. (See
         <a class="medical medical_review" href="/z/d/html/2699.html" rel="external">
          "
          <i>
           Clostridioides difficile
          </i>
          infection in adults: Clinical manifestations and diagnosis", section on 'Diagnostic laboratory assays'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7893.html" rel="external">
          "Diagnosis of and screening for hypothyroidism in nonpregnant adults", section on 'Diagnosis'
         </a>
         and
         <a class="local">
          'Etiology and pathogenesis'
         </a>
         above.)
        </p>
        <p>
         There are no pathognomonic laboratory findings in patients with acute pseudo-obstruction. Laboratory evaluation may reveal leukocytosis and metabolic abnormalities. If present, leukocytosis is usually due to the patient's underlying disease or impending perforation and is not associated with an uncomplicated pseudo-obstruction. Metabolic abnormalities, especially hypokalemia, hypocalcemia, and hypomagnesemia, are common, occurring in more than 50 percent of patients [
         <a href="#rid1">
          1,16-18,22,23
         </a>
         ]. (See
         <a class="local">
          'Supportive care'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H109746738">
         <span class="h3">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         We perform an abdominal computed tomography (CT) scan to establish the diagnosis of acute intestinal pseudo-obstruction and to rule out other causes of intestinal obstruction. In the absence of access to a CT scan, a contrast enema using a water-soluble contrast can be used to establish the diagnosis, provided that there is no evidence of peritonitis on physical examination.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Abdominal CT scan
         </strong>
         – On abdominal CT scan in patients with acute colonic pseudo-obstruction, there is proximal colonic dilatation, often with an intermediate transitional zone at or adjacent to the splenic flexure and a characteristically absent structural cause of colonic obstruction. Occasionally, dilation may extend to the rectum. In addition to differentiating acute colonic pseudo-obstruction from a mechanical obstruction, abdominal CT also has the advantage of demonstrating other intra-abdominal pathology that may have precipitated its development (eg, retroperitoneal hemorrhage).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contrast enema
         </strong>
         – Contrast enema with a water-soluble contrast demonstrates colonic dilation in the absence of a mechanical obstruction. While contrast enema can potentially cause an osmotically driven evacuation of the colon and relieve the pseudo-obstruction, they can increase intracolonic pressure and cause perforation [
         <a href="#rid24">
          24
         </a>
         ]. Contrast enemas should not be performed in patients with possible peritonitis. (See
         <a class="medical medical_review" href="/z/d/html/1381.html" rel="external">
          "Toxic megacolon", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1607233070">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis is established by abdominal CT scan, which demonstrates proximal colonic dilatation, often with an intermediate transitional zone at or adjacent to the splenic flexure and a characteristically absent structural cause of colonic obstruction. Occasionally, dilation may extend to the rectum. Colonoscopy should not be used to make the diagnosis of acute intestinal pseudo-obstruction as insufflation of air may increase the colonic dilatation.
        </p>
        <p class="headingAnchor" id="H1318075295">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of acute colonic pseudo-obstruction includes other causes of acute colonic dilation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanical
         </strong>
         <strong>
          obstruction
         </strong>
         — Patients with mechanical obstruction frequently complain of crampy abdominal pain; however, lack of pain, especially in the older adult or postoperative patient receiving opiates, does not exclude that diagnosis. A "cut-off sign" (lack of gas in the distal colon or rectum) or small bowel air-fluid levels on abdominal radiographs can also be seen in patients with acute colonic pseudo-obstruction. However, a mechanical obstruction can be differentiated from acute colonic pseudo-obstruction by visualization of an obstructing lesion on abdominal CT or contrast enema. (See
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxic megacolon
         </strong>
         — Unlike patients with acute intestinal pseudo-obstruction, patients with toxic megacolon have evidence of significant systemic toxicity with fever, tachycardia, and altered sensorium, as well as abdominal pain. Patients with toxic megacolon often have a history of severe bloody diarrhea or other signs or symptoms of chronic inflammatory bowel disease. On abdominal upright and plain films, there is evidence of colonic distension, but the normal colonic haustral pattern is either absent or severely disturbed with "thumbprinting" due to the presence of submucosal edema or thickening of the colonic wall. (See
         <a class="medical medical_review" href="/z/d/html/1381.html" rel="external">
          "Toxic megacolon", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H452331834">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goal of management is to decompress the colon in order to minimize the risk of colonic perforation and ischemia. There are few controlled trials comparing treatments of acute colonic pseudo-obstruction. Our recommendations are largely consistent with guidelines for the management of acute colonic pseudo-obstruction by the American Society for Gastrointestinal Endoscopy and the American Society of Colon and Rectal Surgeons  (
         <a class="graphic graphic_algorithm graphicRef138695" href="/z/d/graphic/138695.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid25">
          25-27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1181553185">
         <span class="h2">
          Patients without ischemia, peritonitis, perforation
         </span>
        </p>
        <p class="headingAnchor" id="H756481187">
         <span class="h3">
          Cecal diameter &lt;12 cm, mild to moderate abdominal pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initial management of acute colonic pseudo-obstruction is usually conservative in patients without significant abdominal pain, extreme (&gt;12 cm) colonic distension, or signs of peritonitis, and those who have one or more potential factors that are reversible  (
         <a class="graphic graphic_algorithm graphicRef138695" href="/z/d/graphic/138695.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2669431759">
         <span class="h4">
          Supportive care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Supportive care with removal of precipitants is the first step in the management of patients with acute colonic pseudo-obstruction [
         <a href="#rid28">
          28
         </a>
         ]. Supportive care includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of the underlying disease (eg, infection, congestive heart failure).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Discontinuation of medications that can decrease colonic motility (eg, opiates, calcium channel blockers, medications with anticholinergic side effects) and avoidance of laxatives [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients should be given nothing by mouth and intravenous fluids to maintain normovolemia and correct electrolyte abnormalities [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decompression of the gastrointestinal tract by placement of a nasogastric tube attached to intermittent suction. Gentle tap water enemas can be administered, but their use should be limited given the risk of perforation [
         <a href="#rid1">
          1,26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Encourage patients to ambulate, if possible. Patients should be placed in a prone position with the hips elevated on a pillow or the knee-chest position with the hips held high. These positions should be alternated with right and left lateral decubitus positions each hour.
        </p>
        <p>
        </p>
        <p>
         Supportive care can be continued for 72 hours in the absence of significant pain, extreme (&gt;12 cm) colonic distension, or signs of peritonitis. Success rates of conservative management alone range from 70 to 90 percent with a mean time to resolution of three days in one series [
         <a href="#rid1">
          1,21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1323004779">
         <span class="h4">
          Monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the risk of colonic ischemia and perforation, we monitor patients with acute colonic pseudo-obstruction with the following [
         <a href="#rid20">
          20
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serial physical examination every 12 to 24 hours.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Plain abdominal radiographs every 12 to 24 hours to evaluate the colonic diameter.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Laboratory tests every 12 to 24 hours, including a complete blood count and electrolytes.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2810662424">
         <span class="h3">
          Cecal diameter &gt; 12 cm, severe abdominal pain, or failure of conservative management
         </span>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h4">
          Neostigmine
         </span>
        </p>
        <p class="headingAnchor" id="H3581998150">
         <span class="h5">
          Initial treatment
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications and contraindications
         </strong>
         –
         <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">
          Neostigmine
         </a>
         , an acetylcholinesterase inhibitor, is indicated in patients with acute colonic pseudo-obstruction and cecal diameter &gt;12 cm or in patients who fail 48 to 72 hours of conservative therapy. In patients with cecal diameter &gt;12 cm and in patients who have failed 72 hours of conservative therapy, we use pharmacologic therapy with neostigmine. Relative contraindications to the use of neostigmine include recent myocardial infarction, acidosis, asthma, bradycardia, peptic ulcer disease, and therapy with beta-blockers. The use of neostigmine in pregnancy, although reported, has not been well studied [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose and administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">
          Neostigmine
         </a>
         (2 to 5 mg) should be delivered by slow intravenous injection over five minutes, with continuous monitoring of vital signs and electrocardiograph for 30 minutes and continuous clinical assessment for 15 to 30 minutes [
         <a href="#rid26">
          26,30
         </a>
         ]. Patients should be kept supine on a bedpan, and
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         should be available at the bedside to treat bradycardia associated with neostigmine [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some side effects (particularly bradycardia and bronchoconstriction) might be reduced by coadministration of
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         , an anticholinergic agent that has limited activity on the muscarinic receptors of the colon [
         <a href="#rid31">
          31
         </a>
         ]. In the author's experience, lower doses (1.5 mg) may also be effective and may be associated with less abdominal cramping, nausea, and vomiting. A further reduction in dosage to 0.5 or 1 mg is indicated in patients with new-onset heart block, a history of second-degree heart block, or following bowel resection with primary anastomosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Subcutaneous administration and continuous infusion of
         <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">
          neostigmine
         </a>
         may be alternatives to bolus dosing, but further studies are needed [
         <a href="#rid32">
          32,33
         </a>
         ]. In one retrospective study of 75 patients, of whom 38 were treated with a continuous infusion of neostigmine, continuous infusion was associated with greater bowel diameter reduction at 24 hours, but was also associated with an increased number of bradycardic events [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications
         </strong>
         – Adverse effects of
         <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">
          neostigmine
         </a>
         include bradycardia, hypotension, asystole, seizures, restlessness, tremor, bronchoconstriction, nausea, vomiting, salivation, diarrhea, sweating, and abdominal cramps.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – In a meta-analysis of four randomized trials that included 127 patients with acute colonic pseudo-obstruction, of which 65 were treated with
         <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">
          neostigmine
         </a>
         , resolution of acute colonic pseudo-obstruction was significantly higher with only one dose of neostigmine as compared with placebo (89 versus 15 percent, number needed to treat 1, 95% CI 1-2) [
         <a href="#rid34">
          34,35
         </a>
         ]. Recurrence rate of acute colonic pseudo-obstruction after an initial response was 0 to 31 percent, with an overall long-term response of 69 to 100 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most patients respond quickly to therapy. In a randomized trial, 21 patients with acute colonic pseudo-obstruction were assigned to treatment with
         <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">
          neostigmine
         </a>
         or placebo. Prompt decompression was observed in 11 patients (91 percent) who received neostigmine compared with none receiving placebo. In patients treated with neostigmine, the median time to response was four minutes (range 3 to 30 minutes) [
         <a href="#rid36">
          36
         </a>
         ]. Recurrence of colonic distension occurred in two patients (11 percent). Male sex, younger age, postsurgical status, and having electrolyte imbalance are risk factors for nonresponse to neostigmine [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3964899057">
         <span class="h5">
          Additional management based on response
         </span>
         <span class="headingEndMark">
          —
         </span>
         Response to
         <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">
          neostigmine
         </a>
         can be assessed clinically and radiographically with a reduction in discomfort, abdominal girth, and colon diameter on abdominal radiographs.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Resolution
         </strong>
         –
         <strong>
         </strong>
         In patients with successful colonic decompression, we administer oral polyethylene glycol daily to decrease the risk of recurrence in accordance with the literature [
         <a href="#rid26">
          26,38
         </a>
         ]; the dose tested in a randomized placebo-controlled clinical trial was 29.5 g polyethylene glycol (PEG) 3350 (PEG3350); the commercially available PEG3350 preparation provides 17 g in a capful dissolved in 240 mL water; therefore, one can administer just under 2 capfuls in 500 mL water orally if tolerated, or by nasogastric tube.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Non-response, partial response, or recurrence
         </strong>
         –
         <strong>
         </strong>
         In patients who fail an initial dose of
         <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">
          neostigmine
         </a>
         , or have a partial response, we administer a second dose of neostigmine after 24 hours before proceeding to colonic decompression. A second dose of neostigmine has been associated with clinical response in 40 to 100 percent of patients [
         <a href="#rid27">
          27,30,38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H109746916">
         <span class="h4">
          Colonoscopic decompression
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications and contraindications
         </strong>
         – We perform colonic decompression in patients with acute colonic pseudo-obstruction who have failed
         <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">
          neostigmine
         </a>
         or who have contraindications to neostigmine [
         <a href="#rid26">
          26,30
         </a>
         ]. The role of adjunctive colonoscopic decompression with supportive therapy and neostigmine in symptomatic patients and patients with proximal colonic dilation has not been established [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Colonic ischemia, perforation, or peritonitis are contraindications to colonoscopic decompression and require surgical management. (See
         <a class="local">
          'Surgical management'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Technique
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Colonoscopic decompression should be performed by an experienced endoscopist using water infusion and minimal to no insufflation of the colon. Carbon dioxide should be used rather than air.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use of narcotics for procedural sedation should be avoided as they can potentiate colonic atony.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The colon should be unprepped. An oral bowel preparation should not be administered prior to colonoscopy due to the risk of aspiration in the presence of pseudo-obstruction. We do not administer enemas prior to the colonoscopy as they are often ineffective because of the dilatation and lack of propulsion in the colon and because they carry a risk of colonic perforation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An attempt should be made to reach at least the distal transverse colon, after which extensive suctioning of air is recommended.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We place a decompression tube with the aid of a guidewire at the time of colonoscopy as this may reduce the need for repeated colonoscopic decompression and allows for colonic administration of polyethylene glycol (PEG) laxative (PEG3350 17 g in 240 mL water) [
         <a href="#rid38">
          38
         </a>
         ]. In order to place a decompression tube, a guidewire is passed through the channel of the colonoscope after reaching the distal transverse colon. Air is suctioned from the colon and the wire left in place as the colonoscope is gently removed. The decompression tube (customized with several extra side holes, if necessary) is then passed over the guidewire and left in the transverse colon. To minimize air inflation, the whole colon should not be examined and the guidewire should not be delivered into the cecum. The decompression tube should be placed to gravity drainage and flushed every four to six hours. The decompression tube can be retained for 24 hours after significant reduction of abdominal distension or consistent passage of flatus in order to ensure resolution rather than having to replace the tube if there is recurrence of the acute colonic pseudo-obstruction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications
         </strong>
         – Colonoscopic decompression is a technically difficult procedure and has a perforation rate of approximately 2 percent and a 1 percent risk of mortality [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – The use of colonoscopic decompression has only been evaluated in patients who have failed conservative treatment and has not been directly compared with
         <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">
          neostigmine
         </a>
         in randomized trials [
         <a href="#rid41">
          41,42
         </a>
         ]. In case series, colonoscopic decompression alone is definitive therapy in less than 50 percent of patients, but, with concurrent placement of a decompression tube, success rates of 88 percent have been reported [
         <a href="#rid16">
          16,21,43,44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3037537482">
         <span class="h2">
          Patients with refractory symptoms, ischemia, perforation, or peritonitis
         </span>
        </p>
        <p class="headingAnchor" id="H3457354238">
         <span class="h3">
          Surgical management
         </span>
         <span class="headingEndMark">
          —
         </span>
         We reserve surgical management for patients with colonic ischemia, perforation, or peritonitis and those that are refractory to medical management [
         <a href="#rid26">
          26
         </a>
         ]. While one study proposed a colon diameter ≥11 cm to be predictive of a lack of therapeutic response to endoscopic treatment and an indication for surgery, these results have not been replicated [
         <a href="#rid45">
          45,46
         </a>
         ].
        </p>
        <p>
         For patients with acute colonic pseudo-obstruction who fail colonoscopic decompression and pharmacologic therapy with
         <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">
          neostigmine
         </a>
         , surgical management consists of stoma creation with or without resection [
         <a href="#rid27">
          27
         </a>
         ]. Patients with perforation or peritonitis require urgent exploration, lavage, or drainage of the peritoneal cavity. The need for and extent of bowel resection, as well as the type of stoma, are dictated by patient anatomy and clinical conditions. (See
         <a class="medical medical_review" href="/z/d/html/15026.html" rel="external">
          "Overview of surgical ostomy for fecal diversion"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1168360516">
         <span class="h3">
          Other approaches
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other approaches have been evaluated in patients with acute colonic pseudo-obstruction, but evidence to support their use is limited.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          Erythromycin
         </a>
         – In case reports, patients with acute intestinal pseudo-obstruction have been treated with erythromycin (250 mg intravenously every eight hours for three days or orally 250 mg four times daily for 10 days), but the responses to treatment have been inconsistent, with only gradual improvement over 12 to 24 hours of therapy [
         <a href="#rid47">
          47,48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Percutaneous colostomy of the cecum
         </strong>
         –
         <strong>
         </strong>
         Percutaneous decompression can be accomplished by endoscopically guided insertion of a plastic tube into the left colon or cecum, allowing decompression and irrigation. Alternatively, tube placement in the right colon requires a combined endoscopic and radiologic approach (fluoroscopic guidance) [
         <a href="#rid19">
          19,26
         </a>
         ]. While percutaneous cecostomy may be effective for treatment of acute colonic pseudo-obstruction, it is invasive and can be complicated by local infection and bleeding [
         <a href="#rid49">
          49-52
         </a>
         ]. In addition, percutaneous decompression has not been directly compared with colonoscopic decompression or surgery.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H980548177">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis in patients with acute intestinal pseudo-obstruction depends on the presence of complications. Colonic ischemia and perforation are the two main complications of acute intestinal pseudo-obstruction, which develop in approximately 3 to 15 percent of patients. The mortality rate in acute intestinal pseudo-obstruction in the absence of complications is approximately 15 percent with early appropriate management as compared with 36 to 44 percent in patients with a perforated or ischemic bowel [
         <a href="#rid1">
          1,30,53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1601525184">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119292.html" rel="external">
          "Society guideline links: Acute colonic pseudo-obstruction (Ogilvie's syndrome)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Acute colonic pseudo-obstruction (Ogilvie's syndrome) is a disorder characterized by acute dilatation of the colon in the absence of an anatomic lesion that obstructs the flow of intestinal contents. Acute colonic pseudo-obstruction usually involves the cecum and right hemicolon, although occasionally colonic dilation extends to the rectum. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etiology
         </strong>
         – Acute colonic pseudo-obstruction usually occurs in hospitalized or institutionalized patients in association with a severe illness or after surgery and in conjunction with a metabolic imbalance or administration of culprit medications  (
         <a class="graphic graphic_table graphicRef66068" href="/z/d/graphic/66068.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Etiology and pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – Patients usually present with abdominal distension that occurs gradually over three to seven days but may develop rapidly within 24 to 48 hours. Patients may also have nausea, vomiting, abdominal pain, constipation, and, paradoxically, diarrhea. Plain and upright abdominal radiographs show a dilated colon, often from the cecum to the splenic flexure and occasionally to the rectum; haustral markings are normal. Complications include colonic ischemia and perforation. The risk of colonic perforation increases when cecal diameter exceeds 10 to 12 cm and when the distention has been present for greater than six days. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above and
         <a class="local">
          'Complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of acute intestinal pseudo-obstruction should be suspected in patients with abdominal distension or pain and a physical examination that reveals a distended and tympanitic abdomen. The diagnosis is established by abdominal computed tomography [CT] scan, which demonstrates proximal colonic dilatation, often with an intermediate transitional zone at or adjacent to the splenic flexure and a characteristically absent structural cause of colonic obstruction. Occasionally, dilation may extend to the rectum. Colonoscopy should not be used to make the diagnosis of acute intestinal pseudo-obstruction as insufflation of air may increase the colonic dilatation. (See
         <a class="local">
          'Diagnostic approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring
         </strong>
         – Given the risk of colonic ischemia and perforation, patients with acute colonic pseudo-obstruction should be carefully monitored with serial physical examinations and plain abdominal radiographs every 12 to 24 hours to evaluate the colonic diameter. In addition, we perform laboratory tests every 12 to 24 hours including a complete blood count and electrolytes. (See
         <a class="local">
          'Monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cecal diameter &lt;12 cm and mild to moderate abdominal pain
         </strong>
         –
         <strong>
         </strong>
         Initial management of acute colonic pseudo-obstruction consists of conservative therapy in patients without significant abdominal pain or signs of peritonitis. Conservative therapy can be continued for approximately 72 hours in the absence of significant abdominal pain or extreme colonic dilatation (&gt;12 cm)  (
         <a class="graphic graphic_algorithm graphicRef138695" href="/z/d/graphic/138695.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Supportive care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cecal diameter &gt;12 cm, severe abdominal pain, or failure of conservative management
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients at risk for perforation (cecal diameter &gt;12 cm) and those who have failed conservative therapy, we suggest pharmacologic therapy with
         <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">
          neostigmine
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). We administer an initial neostigmine dose (2 mg intravenously over three to five minutes) with cardiac monitoring and administer a second dose of neostigmine (2 mg intravenously over three to five minutes) after 24 hours in patients with a partial response or recurrence after initial resolution. (See
         <a class="local">
          'Neostigmine'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We reserve colonoscopic decompression in patients who fail or who have contraindications to
         <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">
          neostigmine
         </a>
         . (See
         <a class="local">
          'Colonoscopic decompression'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Refractory symptoms, ischemia, perforation, or peritonitis
         </strong>
         – We perform surgical decompression (stoma creation with or without resection) for patients with acute colonic pseudo-obstruction who fail colonoscopic decompression and pharmacologic therapy with
         <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">
          neostigmine
         </a>
         . Patients with perforation or peritonitis require urgent exploration, lavage, or drainage of the peritoneal cavity. (See
         <a class="local">
          'Patients with refractory symptoms, ischemia, perforation, or peritonitis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Vanek VW, Al-Salti M. Acute pseudo-obstruction of the colon (Ogilvie's syndrome). An analysis of 400 cases. Dis Colon Rectum 1986; 29:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JW, Bang KW, Jang PS, et al. Neostigmine for the treatment of acute colonic pseudo-obstruction (ACPO) in pediatric hematologic malignancies. Korean J Hematol 2010; 45:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnston G, Vitikainen K, Knight R, et al. Changing perspective on gastrointestinal complications in patients undergoing cardiac surgery. Am J Surg 1992; 163:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norwood MG, Lykostratis H, Garcea G, Berry DP. Acute colonic pseudo-obstruction following major orthopaedic surgery. Colorectal Dis 2005; 7:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross SW, Oommen B, Wormer BA, et al. Acute Colonic Pseudo-obstruction: Defining the Epidemiology, Treatment, and Adverse Outcomes of Ogilvie's Syndrome. Am Surg 2016; 82:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delmer A, Cymbalista F, Bauduer F, et al. Acute colonic pseudo-obstruction (Ogilvie's syndrome) during induction treatment with chemotherapy and all-trans-retinoic acid for acute promyelocytic leukemia. Am J Hematol 1995; 49:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xie H, Peereboom DM. Ogilvie's syndrome during chemotherapy with high-dose methotrexate for primary CNS lymphoma. J Clin Oncol 2012; 30:e192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sreter KB, Barisic B, Popovic-Grle S. Pharmacogenomics and tailored polypharmacy: an 80-year-old lady with rosuvastatin-associated rhabdomyolysis and maprotiline-related Ogilvie's syndrome . Int J Clin Pharmacol Ther 2017; 55:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jayaram P, Mohan M, Lindow S, Konje J. Postpartum Acute Colonic Pseudo-Obstruction (Ogilvie's Syndrome): A systematic review of case reports and case series. Eur J Obstet Gynecol Reprod Biol 2017; 214:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almueilo SH, Alsulaiman RM. Acute colonic pseudo-obstruction caused by mycophenolate mofetil in a kidney transplant recipient. Exp Clin Transplant 2015; 13:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wrenn SM, Parsons CS, Yang M, Malhotra AK. Acute large bowel pseudo-obstruction due to atrophic visceral myopathy: A case report. Int J Surg Case Rep 2017; 33:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shera IA, Vyas A, Bhat MS, Yousuf Q. Unusual case of Hashimoto's encephalopathy and pseudo-obstruction in a patient with undiagnosed hypothyroidism: a case report. J Med Case Rep 2014; 8:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung JY, Park JS, Kim YS. A Rare Cause of Acute Colonic Pseudo-obstruction: Ogilvie's Syndrome Caused by Herpes Zoster. J Neurogastroenterol Motil 2017; 23:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Natalini J, Borno H, Jin L, Jensen T. An unusual manifestation of diabetic ketoacidosis and acute colonic pseudo-obstruction. JRSM Open 2017; 8:2054270417698632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogilvie WH. William Heneage Ogilvie 1887-1971. Large-intestine colic due to sympathetic deprivation. A new clinical syndrome. Dis Colon Rectum 1987; 30:984.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jetmore AB, Timmcke AE, Gathright JB Jr, et al. Ogilvie's syndrome: colonoscopic decompression and analysis of predisposing factors. Dis Colon Rectum 1992; 35:1135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Dinter TG Jr, Fuerst FC, Richardson CT, et al. Stimulated active potassium secretion in a patient with colonic pseudo-obstruction: a new mechanism of secretory diarrhea. Gastroenterology 2005; 129:1268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bazerbachi F, Haffar S, Szarka LA, et al. Secretory diarrhea and hypokalemia associated with colonic pseudo-obstruction: A case study and systematic analysis of the literature. Neurogastroenterol Motil 2017; 29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saunders MD. Acute colonic pseudo-obstruction. Best Pract Res Clin Gastroenterol 2007; 21:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson CD, Rice RP, Kelvin FM, et al. The radiologic evaluation of gross cecal distension: emphasis on cecal ileus. AJR Am J Roentgenol 1985; 145:1211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sloyer AF, Panella VS, Demas BE, et al. Ogilvie's syndrome. Successful management without colonoscopy. Dig Dis Sci 1988; 33:1391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simon M, Duong JP, Mallet V, et al. Over-expression of colonic K+ channels associated with severe potassium secretory diarrhoea after haemorrhagic shock. Nephrol Dial Transplant 2008; 23:3350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandle GI, Hunter M. Apical potassium (BK) channels and enhanced potassium secretion in human colon. QJM 2010; 103:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schermer CR, Hanosh JJ, Davis M, Pitcher DE. Ogilvie's syndrome in the surgical patient: a new therapeutic modality. J Gastrointest Surg 1999; 3:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogel JD, Feingold DL, Stewart DB, et al. Clinical Practice Guidelines for Colon Volvulus and Acute Colonic Pseudo-Obstruction. Dis Colon Rectum 2016; 59:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naveed M, Jamil LH, Fujii-Lau LL, et al. American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in the management of acute colonic pseudo-obstruction and colonic volvulus. Gastrointest Endosc 2020; 91:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alavi K, Poylin V, Davids JS, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colonic Volvulus and Acute Colonic Pseudo-Obstruction. Dis Colon Rectum 2021; 64:1046.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eisen GM, Baron TH, Dominitz JA, et al. Acute colonic pseudo-obstruction. Gastrointest Endosc 2002; 56:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rausch ME, Troiano NH, Rosen T. Use of neostigmine to relieve a suspected colonic pseudoobstruction in pregnancy. J Perinatol 2007; 27:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saunders MD, Kimmey MB. Systematic review: acute colonic pseudo-obstruction. Aliment Pharmacol Ther 2005; 22:917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korsten MA, Rosman AS, Ng A, et al. Infusion of neostigmine-glycopyrrolate for bowel evacuation in persons with spinal cord injury. Am J Gastroenterol 2005; 100:1560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smedley LW, Foster DB, Barthol CA, et al. Safety and Efficacy of Intermittent Bolus and Continuous Infusion Neostigmine for Acute Colonic Pseudo-Obstruction. J Intensive Care Med 2020; 35:1039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kram B, Greenland M, Grant M, et al. Efficacy and Safety of Subcutaneous Neostigmine for Ileus, Acute Colonic Pseudo-obstruction, or Refractory Constipation. Ann Pharmacother 2018; 52:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valle RG, Godoy FL. Neostigmine for acute colonic pseudo-obstruction: A meta-analysis. Ann Med Surg (Lond) 2014; 3:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kayani B, Spalding DR, Jiao LR, et al. Does neostigmine improve time to resolution of symptoms in acute colonic pseudo-obstruction? Int J Surg 2012; 10:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ponec RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med 1999; 341:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehta R, John A, Nair P, et al. Factors predicting successful outcome following neostigmine therapy in acute colonic pseudo-obstruction: a prospective study. J Gastroenterol Hepatol 2006; 21:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sgouros SN, Vlachogiannakos J, Vassiliadis K, et al. Effect of polyethylene glycol electrolyte balanced solution on patients with acute colonic pseudo obstruction after resolution of colonic dilation: a prospective, randomised, placebo controlled trial. Gut 2006; 55:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mankaney GN, Sarvepalli S, Arora Z, et al. Colonic Decompression Reduces Proximal Acute Colonic Pseudo-obstruction and Related Symptoms. Dis Colon Rectum 2020; 63:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vantrappen G. Acute colonic pseudo-obstruction. Lancet 1993; 341:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peker KD, Cikot M, Bozkurt MA, et al. Colonoscopic decompression should be used before neostigmine in the treatment of Ogilvie's syndrome. Eur J Trauma Emerg Surg 2017; 43:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsirline VB, Zemlyak AY, Avery MJ, et al. Colonoscopy is superior to neostigmine in the treatment of Ogilvie's syndrome. Am J Surg 2012; 204:849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rex DK. Acute colonic pseudo-obstruction (Ogilvie's syndrome). Gastroenterologist 1994; 2:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geller A, Petersen BT, Gostout CJ. Endoscopic decompression for acute colonic pseudo-obstruction. Gastrointest Endosc 1996; 44:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joechle K, Guenzle J, Utzolino S, et al. Ogilvie's syndrome-is there a cutoff diameter to proceed with upfront surgery? Langenbecks Arch Surg 2022; 407:1173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu JJ, Venkatesh V, Gao J, et al. Efficacy and Safety of Neostigmine and Decompressive Colonoscopy for Acute Colonic Pseudo-Obstruction: A Single-Center Analysis. Gastroenterology Res 2021; 14:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonacini M, Smith OJ, Pritchard T. Erythromycin as therapy for acute colonic pseudo-obstruction (Ogilvie's syndrome). J Clin Gastroenterol 1991; 13:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armstrong DN, Ballantyne GH, Modlin IM. Erythromycin for reflex ileus in Ogilvie's syndrome. Lancet 1991; 337:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           vanSonnenberg E, Varney RR, Casola G, et al. Percutaneous cecostomy for Ogilvie syndrome: laboratory observations and clinical experience. Radiology 1990; 175:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cowlam S, Watson C, Elltringham M, et al. Percutaneous endoscopic colostomy of the left side of the colon. Gastrointest Endosc 2007; 65:1007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramage JI Jr, Baron TH. Percutaneous endoscopic cecostomy: a case series. Gastrointest Endosc 2003; 57:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saunders MD, Kimmey MB. Colonic pseudo-obstruction: the dilated colon in the ICU. Semin Gastrointest Dis 2003; 14:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DAVIS L, LOWMAN RM. An evaluation of cecal size in impending perforation of the cecum. Surg Gynecol Obstet 1956; 103:711.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2531 Version 18.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3753674" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Acute pseudo-obstruction of the colon (Ogilvie's syndrome). An analysis of 400 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21120165" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Neostigmine for the treatment of acute colonic pseudo-obstruction (ACPO) in pediatric hematologic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1575312" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Changing perspective on gastrointestinal complications in patients undergoing cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16108888" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Acute colonic pseudo-obstruction following major orthopaedic surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26874130" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Acute Colonic Pseudo-obstruction: Defining the Epidemiology, Treatment, and Adverse Outcomes of Ogilvie's Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7741149" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Acute colonic pseudo-obstruction (Ogilvie's syndrome) during induction treatment with chemotherapy and all-trans-retinoic acid for acute promyelocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22711852" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Ogilvie's syndrome during chemotherapy with high-dose methotrexate for primary CNS lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28257284" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Pharmacogenomics and tailored polypharmacy: an 80-year-old lady with rosuvastatin-associated rhabdomyolysis and maprotiline-related Ogilvie's syndrome .
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28531835" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Postpartum Acute Colonic Pseudo-Obstruction (Ogilvie's Syndrome): A systematic review of case reports and case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24918432" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Acute colonic pseudo-obstruction caused by mycophenolate mofetil in a kidney transplant recipient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28285209" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Acute large bowel pseudo-obstruction due to atrophic visceral myopathy: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25194644" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Unusual case of Hashimoto's encephalopathy and pseudo-obstruction in a patient with undiagnosed hypothyroidism: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28992679" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A Rare Cause of Acute Colonic Pseudo-obstruction: Ogilvie's Syndrome Caused by Herpes Zoster.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28620506" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : An unusual manifestation of diabetic ketoacidosis and acute colonic pseudo-obstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3319452" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : William Heneage Ogilvie 1887-1971. Large-intestine colic due to sympathetic deprivation. A new clinical syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1473414" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Ogilvie's syndrome: colonoscopic decompression and analysis of predisposing factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16230079" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Stimulated active potassium secretion in a patient with colonic pseudo-obstruction: a new mechanism of secretory diarrhea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28580600" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Secretory diarrhea and hypokalemia associated with colonic pseudo-obstruction: A case study and systematic analysis of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17643908" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Acute colonic pseudo-obstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3877425" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The radiologic evaluation of gross cecal distension: emphasis on cecal ileus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3180976" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Ogilvie's syndrome. Successful management without colonoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18653901" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Over-expression of colonic K+ channels associated with severe potassium secretory diarrhoea after haemorrhagic shock.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19892809" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Apical potassium (BK) channels and enhanced potassium secretion in human colon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10457342" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Ogilvie's syndrome in the surgical patient: a new therapeutic modality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27270510" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Clinical Practice Guidelines for Colon Volvulus and Acute Colonic Pseudo-Obstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31791596" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in the management of acute colonic pseudo-obstruction and colonic volvulus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34016826" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colonic Volvulus and Acute Colonic Pseudo-Obstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12447286" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Acute colonic pseudo-obstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17377607" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Use of neostigmine to relieve a suspected colonic pseudoobstruction in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16268965" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Systematic review: acute colonic pseudo-obstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15984982" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Infusion of neostigmine-glycopyrrolate for bowel evacuation in persons with spinal cord injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30373445" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Safety and Efficacy of Intermittent Bolus and Continuous Infusion Neostigmine for Acute Colonic Pseudo-Obstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29359574" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Efficacy and Safety of Subcutaneous Neostigmine for Ileus, Acute Colonic Pseudo-obstruction, or Refractory Constipation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25568788" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Neostigmine for acute colonic pseudo-obstruction: A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22985773" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Does neostigmine improve time to resolution of symptoms in acute colonic pseudo-obstruction?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10403850" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Neostigmine for the treatment of acute colonic pseudo-obstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16509875" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Factors predicting successful outcome following neostigmine therapy in acute colonic pseudo-obstruction: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16306137" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Effect of polyethylene glycol electrolyte balanced solution on patients with acute colonic pseudo obstruction after resolution of colonic dilation: a prospective, randomised, placebo controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31567918" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Colonic Decompression Reduces Proximal Acute Colonic Pseudo-obstruction and Related Symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8093750" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Acute colonic pseudo-obstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27432173" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Colonoscopic decompression should be used before neostigmine in the treatment of Ogilvie's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23021196" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Colonoscopy is superior to neostigmine in the treatment of Ogilvie's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7987621" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Acute colonic pseudo-obstruction (Ogilvie's syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8858319" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Endoscopic decompression for acute colonic pseudo-obstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35020083" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Ogilvie's syndrome-is there a cutoff diameter to proceed with upfront surgery?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34267830" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Efficacy and Safety of Neostigmine and Decompressive Colonoscopy for Acute Colonic Pseudo-Obstruction: A Single-Center Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1918858" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Erythromycin as therapy for acute colonic pseudo-obstruction (Ogilvie's syndrome)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1671288" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Erythromycin for reflex ileus in Ogilvie's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2343112" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Percutaneous cecostomy for Ogilvie syndrome: laboratory observations and clinical experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17531635" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Percutaneous endoscopic colostomy of the left side of the colon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12709715" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Percutaneous endoscopic cecostomy: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12610851" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Colonic pseudo-obstruction: the dilated colon in the ICU.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13380697" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : An evaluation of cecal size in impending perforation of the cecum.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
